IRVINE, Calif., Jan. 31, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX ), developer of minimally invasive treatments for aortic disorders, announced today the publication of favorable clinical results for the Nellix technology for the endovascular repair of abdominal aortic aneurysm (EVAR). The peer-reviewed article reported initial results from the international multicenter clinical trial, with successful aneurysm exclusion in all patients, and no late aneurysm or device-related adverse events or secondary procedures.
Lead author and scientific advisor Carlos E. Donayre, MD (Harbor-UCLA Medical Center, Torrance, CA) commented, "The Nellix technology was designed to address the limitations of currently available EVAR devices and to expand the therapy to more patients. By filling the aneurysm sac, the Nellix device may reduce the incidence of endoleaks, secondary interventions and the need for annual CT scan follow-up. We are encouraged by these promising results, and look forward to the availability of broader experience in the near future."
The publication, entitled "Initial clinical experience with a sac anchoring endoprosthesis for aortic aneurysm repair," was published in the February issue of the Journal of Vascular Surgery (JVS). The study examined the initial and one year outcomes of 21 patients treated at four international centers. An independent core laboratory analyzed preoperative and post-procedural computed tomography scans to determine aneurysm exclusion and device stability over time.
John McDermott, President and Chief Executive Officer said, "We believe the Nellix technology represents the next generation in endovascular repair of abdominal aortic aneurysms. Since completing the acquisition in December 2010, we are delighted that initial results of the international trial are now published by a peer revie